Stereotaxis, Inc. (STXS)
Stock Price:
$4.15 USD
0.30 (7.79%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
Pre-market: $4.14 -0.01 (-0.24%) Aug 4, 7:00 AM
Key Info
| Market Cap |
301.71M |
| Revenue (ttm) |
27.65M |
| Net Income (ttm) |
-4.44M |
| Shares Out |
72.70M |
| EPS (ttm) |
-0.09 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$4.15 |
| Previous Close |
$3.85 |
| Change ($) |
0.30 |
| Change (%) |
7.79% |
| Day's Open |
3.80 |
| Day's Range |
3.80 - 4.19 |
| Day's Volume |
342,014 |
| 52-Week Range |
1.70 - 5.82 |
More Stats
| Market Cap |
301.71M |
| Enterprise Value |
277.52M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
72.70M |
| Float |
37.17M |
| EPS (basic) |
-0.09 |
| EPS (diluted) |
-0.09 |
| FCF / Share |
-0.07 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.09M |
| Short Ratio |
3.41 |
| Short % of Float |
5.46% |
| Beta |
1.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.91 |
| PB Ratio |
12.91 |
| Revenue |
27.65M |
| Operating Income |
-4.74M |
| Net Income |
-4.44M |
| Free Cash Flow |
-5.03M |
| Net Cash |
24.18M |
| Net Cash / Share |
0.33 |
| Gross Margin |
82.34% |
| Operating Margin |
-17.14% |
| Profit Margin |
-21.20% |
| FCF Margin |
-18.17% |
| ROA |
-9.27% |
| ROE |
-27.23% |
| ROIC |
-86.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$7.50*
(80.72% upside)
Low
6.00
Current: $4.15
High
9.00
Target: 7.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 28.90 | 29.35 | 31.14 | 32.16 | 37.67 | 35.01 | 38.03 | 46.56 | 41.99 | 54.05 |
| Revenue Growth | -1.51% | -5.77% | -3.17% | -14.63% | 7.61% | -7.94% | -18.32% | 10.9% | -22.32% | - |
| Gross Profit | 22.77 | 23.63 | 20.39 | 24.63 | 27.24 | 26.79 | 27.03 | 31.78 | 29.49 | 38.49 |
| Operating Income | -4.83 | -2.46 | -5.92 | -6.43 | -5.41 | -5.38 | -8.84 | -10.63 | -31.94 | -18.96 |
| Net Income | -4.59 | 0.12 | -5.89 | -5.29 | -7.35 | -5.20 | -68.76 | -9.24 | -32.03 | -19.92 |
| Shares Outstanding | 63.05 | 52.08 | 22.61 | 21.81 | 21.11 | 19.95 | 11.55 | 6.94 | 5.48 | 5.05 |
| Earnings Per Share | -0.10 | -0.03 | -0.32 | -0.54 | -0.35 | -0.26 | -5.95 | -1.33 | -5.84 | -3.94 |
| Operating Cash Flow | -4.62 | -2.55 | -4.67 | -6.56 | -2.53 | -9.09 | -6.33 | -12.12 | -31.57 | -18.91 |
| Capital Expenditures | -0.03 | -0.27 | -0.08 | -0.41 | -0.15 | -0.12 | - | -0.13 | -1.03 | -0.72 |
| Free Cash Flow | -4.65 | -2.81 | -4.76 | -6.97 | -2.68 | -9.22 | -6.33 | -12.25 | -32.60 | -19.63 |
| Cash & Equivalents | 30.18 | 10.80 | 3.69 | 8.50 | 5.59 | 7.27 | 13.78 | 7.78 | 13.95 | 35.25 |
| Total Debt | 4.34 | - | - | - | 18.08 | 18.39 | 18.53 | 29.09 | 38.46 | 28.89 |
| Net Cash / Debt | 25.84 | 10.80 | 3.69 | 8.50 | -12.49 | -11.12 | -4.76 | -21.31 | -24.51 | 6.35 |
| Assets | 43.58 | 18.51 | 10.67 | 20.97 | 18.88 | 23.88 | 31.08 | 32.17 | 39.93 | 65.76 |
| Liabilities | 15.06 | 11.24 | 31.27 | 36.50 | 36.50 | 36.43 | 42.78 | 50.96 | 58.76 | 55.29 |
| Book Value | 22.77 | 1.31 | -26.57 | -21.49 | -17.63 | -12.55 | -11.70 | -18.79 | -18.83 | 10.48 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Stereotaxis, Inc. |
| Country |
United States |
| Employees |
118 |
| CEO |
David Leo Fischel |
Stock Information
| Ticker Symbol |
STXS |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NYSEAMERICAN: STXS |
| IPO Date |
August 12, 2004 |
Description
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to design and develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.